Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA)
Read time: 1 mins
Last updated:12th Apr 2012
The primary hypothesis of the CABANA trial is that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of eliminating atrial fibrillation (AF) is superior to current state-of-the-art medical therapy with either rate control or rhythm control drugs for reducing total mortality (primary endpoint) and decreasing the composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest (key secondary endpoint) in patients with untreated or incompletely treated AF warranting therapy. It is anticipated that treatment with percutaneous left atrial catheter ablation will reduce mortality with ? 30% compared to drug therapy. All endpoints will be carefully assessed and analyzed on an intention to treat basis.
|Study start date||2012-04-12|